E&L testing has become essential in pharmaceutical packaging, as FDA, EMA, and ICH regulations drive compliance and ensure safety for biologics, medical devices, and drug delivery systems.
When patients trust a medicine, they’re also trusting the unseen packaging that protects it from production to delivery. One area drawing increasing attention is Extractables and Leachables (E&L) testing, a once-specialized practice that has now become a cornerstone of pharmaceutical quality assurance.
From prefilled syringes and inhalers to ointments and IV bags, manufacturers today must prove that their container closure systems are compatible, safe, and reliable. This shift reflects a broader trend: regulators and industry leaders are no longer viewing E&L testing as optional but essential.
Why E&L Testing Matters
At its core, E&L testing assesses the potential migration of chemical compounds from packaging materials into drug products.
- Extractables are chemical compounds that can be forced out under aggressive testing conditions.
- Leachables are the substances that migrate into the product during storage or real-use conditions.
Both present serious risks: toxicity, reduced drug efficacy, and unwanted interactions that could compromise patient safety. For biologics and other complex therapies, even minor interactions with packaging can have major consequences.
Global Regulatory Momentum
The rise of E&L testing is strongly tied to regulatory expectations. Authorities such as the U.S. FDA, EMA, and China’s NMPA have raised the bar with stringent requirements, supported by standards like:
- USP <1663> (Assessment of Extractables)
- USP <1664> (Assessment of Leachables)
- ISO 10993 (Biological evaluation of medical devices)
Beyond these, regions including India, Brazil, and South Africa are aligning with harmonized frameworks, reinforcing the global relevance of E&L testing. For manufacturers, this means compliance is no longer confined to one market but a worldwide mandate.
Trends Driving Demand for E&L Testing
Several converging industry trends are pushing E&L testing from niche to mainstream:
- Biologics boom: Sensitive to even trace contamination, biologics require packaging compatibility validation.
- Combination products: Auto-injectors, inhalers, and drug-device hybrids are subject to dual scrutiny.
- Sustainability shift: Eco-friendly packaging introduces new materials that must undergo rigorous safety evaluation.
- Pharma 4.0 integration: E&L data is increasingly tied into digital quality management and real-time traceability systems.
Technology and Innovation in E&L
The tools supporting E&L testing have advanced rapidly. Modern labs now rely on mass spectrometry, headspace GC-MS, LC-MS/MS, and NMR to detect even trace-level contaminants with precision.
Meanwhile, in silico toxicological risk assessment tools are helping reduce the reliance on animal testing while speeding up regulatory approval. This combination of sensitivity, speed, and ethical alignment is shaping the next generation of E&L testing strategies.
Leading global providers like Nelson Labs, Intertek, and Eurofins are expanding service capabilities, while emerging CROs across Asia are delivering cost-efficient, compliant solutions for the world’s fastest-growing pharmaceutical markets.
The ICH Q3E Guideline
The upcoming ICH Q3E guideline on Extractables and Leachables, expected by 2026, is set to bring even more structure and consistency to global E&L requirements. Manufacturers are already taking proactive steps by investing in early packaging compatibility studies to mitigate the risk of costly recalls, regulatory delays, or patient safety concerns.
The shift is clear: E&L testing is no longer a last-minute compliance checkbox and it’s becoming a strategic pillar of drug development.
The pharmaceutical and medical device industries are only growing in complexity. As biologics, novel therapies, and sustainable materials expand the landscape. Extractables and Leachables testing has become the new norm.
It delivers more than compliance, it builds trust among regulators, healthcare providers, and, most importantly, patients.
We support pharmaceutical innovators with comprehensive E&L testing services, combining advanced technology, regulatory expertise, and global reach. Whether you’re preparing for the next wave of biologics or ensuring compliance with emerging standards, our team helps you stay ahead with confidence.
Ensure your packaging meets tomorrow’s standards today. Partner with Shiva Analyticals and Neotron for expert E&L testing that protects patients and products today.
About Neotron
Neotron is a premier European provider of analytical services, specializing in food, feed, pharmaceuticals, and cosmetics. With a focus on precise testing, sensory analysis, and R&D, Neotron ensures compliance with the highest global standards. As an accredited lab Neotron delivers innovative, tailored solutions to meet the diverse product development and quality control needs of its clients.